Aquestive Therapeutics, Inc. AQST Deferred Tax Assets, Operating Loss Carryforwards
Deferred Tax Assets, Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.
The official record: Aquestive Therapeutics, Inc.’s 10-K, filed March 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards?
- Aquestive Therapeutics, Inc. (AQST) reported deferred tax assets, operating loss carryforwards of $48.76M in Q4 2025.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s deferred tax assets, operating loss carryforwards has grown at a 34.1% compound annual growth rate (CAGR), from $27.12M to $48.76M.